Patents by Inventor Olaf Mundigl

Olaf Mundigl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST HUMAN EPO RECEPTOR
    Publication number: 20110165592
    Abstract: An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue.
    Type: Application
    Filed: August 28, 2009
    Publication date: July 7, 2011
    Applicant: Hoffman-La Roche. Inc.
    Inventors: Michael Jarsch, Manfred Kubbies, Olaf Mundigl, Nora Torres-Nagel
  • ANTIBODIES AGAINST HUMAN EPO RECEPTOR
    Publication number: 20110143372
    Abstract: An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue.
    Type: Application
    Filed: February 25, 2011
    Publication date: June 16, 2011
    Applicant: Hoffman-La Roche, Inc.
    Inventors: Michael Jarsch, Manfred Kubbies, Olaf Mundigl, Nora Torres-Nagel
  • USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES
    Publication number: 20110059093
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Application
    Filed: June 3, 2010
    Publication date: March 10, 2011
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraeml
  • ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF
    Publication number: 20090275126
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
    Type: Application
    Filed: July 17, 2009
    Publication date: November 5, 2009
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Antibody selection method against IGF-IR
    Patent number: 7579157
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing the antibodies, and uses for the antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: August 25, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Antibodies against insulin-like growth factor I receptor and uses thereof
    Patent number: 7572897
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: August 11, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF
    Publication number: 20080132686
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 5, 2008
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Antibodies against insulin-like growth factor 1 receptor and uses thereof
    Patent number: 7378503
    Abstract: Antibodies which bind to IGF-IR and inhibit the binding of IGF-I and IGF-II to IGF-IR are characterized. These antibodies are implicated in anti-tumor therapy.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: May 27, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Thiophene hydroxamic acid derivatives
    Patent number: 7098241
    Abstract: The (R) and (S) enantiomers of a compound of formula I are novel antiproliferative therapeutic agents. These compounds have HDAC inhibitor activity and are useful in the treatment of cancer. Also disclosed are methods of making and using compounds of formula (I), as well as pharmaceutical compositions containing compounds of formula (I).
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: August 29, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Adelbert Grossmann, Frank Herting, Matthias Koerner, Klaus-Peter Kuenkele, Anja Limberg, Olaf Mundigl, Ulrich Tibes
  • Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
    Patent number: 7091229
    Abstract: A compound of formula (I) wherein A and B are optionally substituted cyclohexenyl or phenyl groups, X is carbonyl or sulfonyl, and Y is 5–7 atoms-linker, is useful as histone deacetylase inhibitors, particularly for inhibiting cell proliferation.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: August 15, 2006
    Assignee: Hoffman-La Roche Inc.
    Inventors: Guy Georges, Adelbert Grossmann, Olaf Mundigl, Wolfgang von der Saal, Tim Sattelkau
  • Antibodies against insulin-like growth factor 1 receptor and uses thereof
    Publication number: 20050008642
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
    Type: Application
    Filed: July 8, 2004
    Publication date: January 13, 2005
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vugt
  • Antibodies against insulin-like growth factor 1 receptor and uses thereof
    Publication number: 20040228859
    Abstract: Antibodies which bind to IGF-IR and inhibit the binding of IGF-I and IGF-II to IGF-IR are characterized. These antibodies are implicated in anti-tumor therapy.
    Type: Application
    Filed: April 1, 2004
    Publication date: November 18, 2004
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
    Patent number: 6800638
    Abstract: A compound of the formula (I) wherein A, R1, R2 and X have the meanings defined in the specification, process of manufacturing such as compound and a pharmaceutical composition with HDAC inhibitor activity and anti-cell proliferation activity containing such a compound.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: October 5, 2004
    Assignee: Hoffman-La Roche Inc.
    Inventors: Guy Georges, Adelbert Grossman, Olaf Mundigl, Wolfgang von der Saal, Tim Sattelkau
  • Thiophene hydroxamic acid derivatives
    Publication number: 20040122079
    Abstract: The (R) and (S) enantiomers of a compound of formula I 1
    Type: Application
    Filed: December 10, 2003
    Publication date: June 24, 2004
    Inventors: Adelbert Grossmann, Frank Herting, Matthias Koerner, Klaus-Peter Kuenkele, Anja Limberg, Olaf Mundigl, Ulrich Tibes
  • Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
    Publication number: 20040077698
    Abstract: A compound of formula (I) wherein A and B are optionally substituted cyclohexenyl or phenyl groups, X is carbonyl or sulfonyl, and Y is 5-7 atoms-linker, is useful as histone deacetylase inhibitors, particularly for inhibiting cell proliferation.
    Type: Application
    Filed: July 24, 2003
    Publication date: April 22, 2004
    Inventors: Guy Georges, Adelbert Grossmann, Olaf Mundigl, Wolfgang von der Saal, Tim Sattelkau
  • Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
    Publication number: 20040053960
    Abstract: A compound of the formula (I) wherein A, R1, R2 and X have the meanings defined in the specification, process of manufacturing such as compound and a pharmaceutical composition with HDAC inhibitor activity and anti-cell proliferation activity containing such a compound.
    Type: Application
    Filed: June 23, 2003
    Publication date: March 18, 2004
    Inventors: Guy Georges, Adelbert Grossman, Olaf Mundigl, Wolfgang von der Saal, Tim Sattelkau
  • Antibodies against SEMP1(p23)
    Patent number: 6627439
    Abstract: Antibody binding to the SEMP1 antigen and characterized in that said antibody binds to SEMP1 in a manner equivalent to an antibody selected from the group of antibodies DSM ACC2458, DSM ACC2459, DSM ACC2461, and DSM ACC2463 is useful for cancer diagnosis and therapy.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: September 30, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thorsten Hoevel, Stefan Koch, Manfred Kubbies, Olaf Mundigl, Petra Rueger
  • Antibodies against SEMP1 (p23)
    Publication number: 20020150574
    Abstract: Antibody binding to the SEMP1 antigen and characterized in that said antibody binds to SEMP1 in a manner equivalent to an antibody selected from the group of antibodies DSM ACC2458, DSM ACC2459, DSM ACC2461, and DSM ACC2463 is useful for cancer diagnosis and therapy.
    Type: Application
    Filed: June 21, 2001
    Publication date: October 17, 2002
    Inventors: Thorsten Hoevel, Stefan Koch, Manfred Kubbies, Olaf Mundigl, Petra Rueger